Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy

Prostate

Volumn 62, Issue 3, 2005, Pages 224-232

  Xu, Chuanliang ^a,b   Jung, Monika ^a   Burkhardt, Mick ^a   Stephan, Carsten ^a   Schnorr, Dietmar ^a   Loening, Stefan ^a   Jung, Klaus ^a   Dietel, Manfred ^a   Kristiansen, Glen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CD59; Immunohistochemistry; Prostate cancer; Protectin; Tumor progression

Indexed keywords

CD59 ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD59; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATROPHY; CANCER RELAPSE; CANCER STAGING; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOLYSIS; CYTOPLASM; GENETIC TRANSCRIPTION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MICRODISSECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STANDARD; TUMOR GROWTH;

ADENOCARCINOMA; AGED; ANTIGENS, CD59; COHORT STUDIES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 12344294466     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20134     Document Type: Article

References (32)

1. Coffey DS. Prostate cancer. An overview of an increasing dilemma. Cancer 1993;71:880-886.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
3. Isaacs WB, De Marzo AM, Nelson WG. Focus on prostate cancer. Cancer Cell 2002;2:113-116.
4. Nelson WG, DeWeese TL, De Marzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002;21:3-16.
5. De Marzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361:955-964.
6. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, Villette JM, Stower MJ, Maitland NJ. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002;52:253-263.
7. Claudio PP, Zamparelli A, Garcia FU, Claudio L, Ammirati G, Farina A, Bovicelli A, Russo G, Giordano GG, McGinnis DE, Giordano A, Cardi G. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. Clin Cancer Res 2002;8:1808-1815.
8. Yamakawa M, Yamada K, Tsuge T, Ohrui H, Ogata T, Dobashi M, Imai Y. Protection of thyroid cancer cells by complement-regulatory factors. Cancer 1994;73:2808-2817.
9. Morgan BP. Effects of the membrane attack complex of complement on nucleated cells. Curr Top Microbiol Immunol 1992;178:115-140.
10. Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 2000;26:269-286.
11. Vose JM. Antibody-targeted therapy for low-grade lymphoma. Semin Hematol 1999;36:15-20.
12. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M. Complement resistance of tumor cells: Basal and induced mechanisms. Mol Immunol 1999;36:929-939.
13. Maio M, Brasoveanu LI, Coral S, Sigalotti L, Lamaj E, Gasparollo A, Visintin A, Altomonte M, Fonsatti E. Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review). Int J Oncol 1998;13:305-318.
14. Goiter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab Invest 1996;74:1039-1049.
15. Brasoveanu LI, Altomonte M, Fonsatti E, Colizzi F, Coral S, Nicotra MR, Cattarossi I, Cattelan A, Natali PG, Maio M. Levels of cell membrane CD59 regulate the extent of complementmediated lysis of human melanoma cells. Lab Invest 1996;74:33-42.
16. Meri S, Lehto T, Sutton CW, Tyynela J, Baumann M. Structural composition and functional characterization of soluble CD59: Heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis. Biochem J 1996;316:923-935.
17. Hakulinen J, Meri S. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest 1994;71:820-827.
18. Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG. Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol 2003;200:633-639.
19. Thorsteinsson L, O'Dowd GM, Harrington PM, Johnson PM. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS 1998;106:869-878.
20. Koretz K, Bruderlein S, Henne C, Moller P. Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Br J Cancer 1993;68:926-931.
21. Hosch SB, Scheunemann P, Luth M, Inndorf S, Stoecklein NH, Erbersdobler A, Rehders A, Gundlach M, Knoefel WT, Izbicki JR. Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer. J Gastrointest Surg 2001;5:673-679.
22. Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S. Complement- regulatory proteins in ovarian malignancies. Int J Cancer 1997;70:14-25.
23. Maenpaa A, Junnikkala S, Hakulinen J, Timonen T, Meri S. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol 1996;148:1139-1152.
24. Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001;24:263-271.
25. Jarvis GA, Li J, Hakulinen J, Brady KA, Nordling S, Dahiya R, Meri S. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 1997;71:1049-1055.
26. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A, Lemoine NR. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002;21(29):4587-4594.
27. Simpson KL, Holmes CH. Differential expression of complement regulatory proteins decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 during human spermatogenesis. Immunology 1994;81:452-461.
28. Liu AY, LaTray L, van Den Engh G. Changes in cell surface molecules associated with in vitro culture of prostatic stromal cells. Prostate 2000;44:303-312.
29. Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 2003;131:254-263.
30. Gelderman KA, Blok VT, Fleuren GJ, Gorter A. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest 2002;82:483-493.
31. Blok VT, Daha MR, Tijsma OM, Weissglas MG, van den Broek LJ, Gorter A. A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Lab Invest 2000;80:335-344.
32. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003;40:109-123.